RAPT Therapeutics Board Changes: New Director Appointed, One Resigns
| Field | Detail |
|---|---|
| Company | Rapt Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Nov 28, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, director-appointment, director-resignation
Related Tickers: RAPT
TL;DR
RAPT's board sees a shuffle: Dr. Hough out, Dr. Meeker in. #BoardChanges
AI Summary
RAPT Therapeutics, Inc. announced on November 24, 2025, a change in its board of directors. Specifically, Dr. Sarah Hough, who served as a Class II Director, has resigned from the board. The company has also appointed Dr. David Meeker as a new Class II Director, effective immediately.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future decision-making.
Risk Assessment
Risk Level: low — This filing reports routine board changes and does not involve financial distress or significant operational shifts.
Key Players & Entities
- RAPT Therapeutics, Inc. (company) — Registrant
- Dr. Sarah Hough (person) — Resigning Class II Director
- Dr. David Meeker (person) — Newly Appointed Class II Director
- November 24, 2025 (date) — Effective date of board changes
FAQ
Who resigned from RAPT Therapeutics' board of directors?
Dr. Sarah Hough resigned from her position as a Class II Director.
When did the board changes become effective?
The changes were effective as of November 24, 2025.
Who was appointed to the RAPT Therapeutics board?
Dr. David Meeker was appointed as a new Class II Director.
What was Dr. Hough's role on the board?
Dr. Hough served as a Class II Director.
What is RAPT Therapeutics' principal executive office address?
The address is 561 Eccles Avenue, South San Francisco, California, 94080.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2025-11-28 14:00:28
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share RAPT The Nasdaq
Filing Documents
- rapt-20251124.htm (8-K) — 41KB
- 0001193125-25-301992.txt ( ) — 144KB
- rapt-20251124.xsd (EX-101.SCH) — 24KB
- rapt-20251124_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAPT Therapeutics, Inc. Date: November 28, 2025 By: /s/ Rodney Young Rodney Young Chief Financial Officer